Compound 4f

Compound 4f is a novel, potent, and reversible monoacylglycerol lipase (MAGL) inhibitor developed by Takeda Pharmaceutical Company. It is designed as a brain-penetrant small molecule that targets the degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG) into arachidonic acid, thereby modulating neuroinflammatory pathways. By inhibiting MAGL, Compound 4f increases 2-AG levels and reduces the production of pro-inflammatory prostaglandins. In preclinical models, it has demonstrated significant neuroprotective and anti-inflammatory effects, showing efficacy in reducing neuronal cell loss and cognitive impairment. The compound is characterized by high selectivity over other serine hydrolases such as fatty acid amide hydrolase (FAAH) and alpha/beta-hydrolase domain-containing protein 6 (ABHD6).

Other names

(2S,4S)-2-((3-((3-chloro-4-methylbenzyl)oxy)azetidine-1-yl)carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one